SecBot SecBot

Increasing Access to Biosimilars Act of 2023

S. 3934 Sen. John Cornyn (R-TX) In committee
Bill text PDF
  1. Introduced Mar 14
  2. Committee Mar 14
  3. Passed Senate Next
  4. Passed House Not yet
  5. To President Not yet
  6. Law Not yet
Where it stands
In committee, Mar 14, 2024Next: Senate vote
958d ago Mar 14, 2024: Read twice and referred to the Committee on Finance.
Final votes
No roll callsNo recorded vote on this bill yet
Lobbying
1company, 1 filing
Subscribe to see spend
Member trades
8trades in the last 90 days
Subscribe to see who
Who backs the bill and who pushes back Subscribe

Companies lobbying on this bill

1 company
Companies by sector
Consumer & Retail 1
Search all 1 companies, their asks and price moves Subscribe

Summary

Increasing Access to Biosimilars Act of 2023

Full summary1 paragraphs

This bill requires the Centers for Medicare & Medicaid Services to establish a demonstration project to evaluate the benefits of providing additional payments to providers of biosimilars under Medicare. Specifically, under the demonstration project, participating providers receive an additional payment based on the difference between the costs to the provider of furnishing the biosimilar and the cost if the provider had furnished the underlying reference biological product instead.

Library of Congress summary, Mar 14, 2024

Summary versions
  • Introduced in SenateMar 14, 2024

Official record from Congress.gov, the House Clerk and the Senate; lobbying from Lobbying Disclosure Act filings. Updated Oct 27, 2026.